A Melbourne-based medical biotech, backed by RMIT University ... iStock Street Talk understands NEXSEN is seeking to raise $2 ...
Biotech HaemaLogiX – which counts former health minister Greg Hunt as a director – is preparing a 2025 ASX listing, as it ...
HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...
The initial public offering (IPO) of Onyx Biotec Limited ended on Monday, November 18, with a strong subscription, fuelled by ...
13don MSN
The list of upcoming IPOs next week includes one mainboard company and two SME public issues which aim to raise funds from ...
Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and ...
Why Is Legend Biotech Corp. (LEGN) Among the Best Up and Coming Stocks to Buy According to Analysts?
With an anticipated strong IPO market in 2025 ... benchmark by 150 percentage points (see more details here). Legend Biotech Corp. (NASDAQ:LEGN) is a clinical-stage biopharmaceutical company ...
Why Is Legend Biotech Corp. (LEGN) Among the Best Up and Coming Stocks to Buy According to Analysts?
In this article, we are going to take a look at where Legend Biotech Corp. (NASDAQ ... companies that have been hesitant to pursue IPOs in 2025, capitalizing on the positive market reaction ...
Biotech investors will ... HaemaLogiX’s preliminary view is that it will raise $50m as part of next year’s IPO. HaemaLogiX, in its current form, has so far raised $24.1m.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback